Hepion Pharmaceuticals

Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing AI-driven therapeutic drugs for the treatment of chronic liver diseases, including non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Their lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. The company has received Fast Track designation from the FDA for rencofilstat for the treatment of NASH and Orphan Drug designation for the treatment of HCC.

Hepion is also developing an AI-POWR™ platform, which combines Artificial Intelligence, Machine Learning, and Deep Learning to decode disease, develop targeted therapies, and select patients that will respond to Hepion therapies. This platform is being used to improve drug target selection, clinical study design, and a priori-responder analysis for their lead drug candidate, rencofilstat. Hepion's focus on AI-driven drug development and their innovative approach to tackling chronic liver diseases positions them as a leader in this growing field.

Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing AI-driven therapeutic drugs for the treatment of chronic liver diseases, including non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Their lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes, and has shown promising results in reducing liver fibrosis and hepatocellular carcinoma tumor burden in experimental models.

Hepion Pharmaceuticals values a culture of innovation, collaboration, and a dedication to tackling chronic liver diseases. They seek energetic and talented professionals who are attracted to challenges and have a track record of delivering outstanding results. The company promotes a spirit of teamwork and a commitment to making a difference in the lives of patients.

Hepion Pharmaceuticals is committed to fostering a workplace that values diversity, equity, and inclusion (DE&I) both internally and within the broader biotechnology industry. They actively support the DE&I principles adopted by the Biotechnology Innovation Organization (BIO) and aim to create a global workforce that reflects the diversity of their customers and patients.